Glenmark receives nod from USFDA for Clindamycin Phosphate Gel USP

Glenmark Pharmaceuticals Limited, a research-led pharma company announced on Thursday that it has received final approval by USFDA for Clindamycin Phosphate Gel USP. 

The company received ANDA approval by United States Food & Drug Administration (USFDA) for Clindamycin Phosphate Gel USP 1 per cent, which is the generic version of Cleocin T 1 Gel, 1 per cent, of Pharmacia & Upjohn. 

For the 12-month period ending December 2020, Cleocin T Gel, 1 per cent, the market achieved annual sales of approximately USD 73.8 million according to IQVIA sales data. 

The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). The formulations business focusses on therapeutic areas namely dermatology, anti-infective, respiratory, cardiac, diabetes, gynaecology, CNS, and oncology. 

Glenmark Pharmaceuticals Ltd enjoys a 15 per cent share in anti-dandruff shampoo, 4.8 per cent in the cardiovascular segment, 2.9 per cent in the pharmaceutical sector, 2.2 per cent in anti-infectives and 2.1 per cent in anti-diabetes. 

The stock of Glenmark Pharmaceuticals ended lower by 0.48 per cent at Rs 505.00 on Thursday.